Giovanni Caforio, M.D., has been a vital part of Bristol-Myers Squibb since 2000, starting as a VP and quickly moving up the ranks to become CEO in 2015. His time as CEO has been marked by a focus on aligning...

Giovanni Caforio, M.D., has been a vital part of Bristol-Myers Squibb since 2000, starting as a VP and quickly moving up the ranks to become CEO in 2015. His time as CEO has been marked by a focus on aligning executive compensation with the company's performance. Interestingly, he has opted out of cash bonuses and market stock grants, instead receiving a stable salary that peaked at over $19 million in 2023. Caforio is set to retire from his CEO role in November 2023 but will continue as Executive Chairman to guide the company during this transition. Under his leadership, Bristol-Myers has leaned heavily into cancer therapies and immuno-oncology, gaining a strong foothold in these crucial markets. Known for his medical background, Caforio's approach blends clinical knowledge with corporate strategy, making him an influential figure at Bristol-Myers Squibb. As the company looks towards new leadership, Caforio leaves behind a legacy focused on long-term growth and shareholder alignment.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Bristol-Myers Squibb CEOs

B

Giovanni Caforio

Ex-CEO of Bristol-Myers Squibb

Education

Medical degree from the University of Rome

Field of Expertise

Healthcare & Life Sciences - Medicine

Sector of Economy

Healthcare

Born

April 17, 1965 - 59 years ago

CEO of Bristol-Myers Squibb for

8 years 5 months (May 2015 - Nov 2023)

Previous Experience

Various senior roles within Bristol-Myers Squibb

Rivals

Competitors/colleagues of Giovanni Caforio

P

Albert Bourla

CEO of Pfizer

2023 Compensation

Stock

$0.00

Salary

$1.79M

Bonus

$0.00

Other

$2.26M

Total Holdings

$18.38M

G

Daniel O'Day

CEO of Gilead Sciences

2023 Compensation

Stock

$16.51M

Salary

$1.74M

Bonus

$0.00

Other

$1.22M

Total Holdings

$103.20M

M

Robert M. Davis

CEO of Merck & Co.

2023 Compensation

Stock

$17.72M

Salary

$1.60M

Bonus

$0.00

Other

$386.15K

Total Holdings

$5.80M

J

Joaquin Duato

CEO of Johnson & Johnson

2023 Compensation

Stock

$0.00

Salary

$1.58M

Bonus

$3.65M

Other

$241.99K

Total Holdings

$61.93M

V

Reshma Kewalramani

CEO of Vertex Pharmaceuticals

2022 Compensation

Stock

$10.64M

Salary

$1.40M

Bonus

$3.78M

Other

$43.06K

Total Holdings

$54.25M

A

Robert A. Bradway

CEO of Amgen

2023 Compensation

Stock

$0.00

Salary

$1.79M

Bonus

$0.00

Other

$680.46K

Total Holdings

$182.86M

Holdings

See how much did Giovanni Caforio make over time.

Giovanni Caforio’s stock holdings at Bristol-Myers Squibb have seen some significant fluctuations between 2020 and 2023. His wealth peaked at approximately $13 million in stock holdings back in 2020, largely due to performance-based awards that vested while his company thrived....

Giovanni Caforio’s stock holdings at Bristol-Myers Squibb have seen some significant fluctuations between 2020 and 2023. His wealth peaked at approximately $13 million in stock holdings back in 2020, largely due to performance-based awards that vested while his company thrived. However, by 2023, Caforio had no new grants or options, indicating a strategic shift as he prepared to pass leadership to a successor. His commitment to long-term value creation is reflected in these holdings as he has consistently maintained a stake that aligns with Bristol-Myers' growth. This highlights his confidence in the company's direction even as he plans to transition away from the chief executive position.

Mar 11, 2025

B

shares

BMY @ $61.62

S

shares

SYK @ $365.40

Total Stock Sold

$46.74M

BMY

$46.74M

720,313 BMY shares

What if they kept their stock?

If Giovanni Caforio didn't sell their stock, today they would have:
Extra BMY720,313 shares worth $41.96M.
This is -10.24% and $4.79M less than what they got when they sold the stock.

Charitable Transactions

BMY

2,409 shares

BMY

Recent Charitable Transactions

BMY

440 shares

BMY

Oct 10, 2023

Charity

BMY

420 shares

BMY

Mar 21, 2022

Charity

BMY

525 shares

BMY

Dec 31, 2021

Charity

BMY

480 shares

BMY

Dec 31, 2020

Charity

BMY

544 shares

BMY

Dec 31, 2019

Charity

Insider Trading

See recent insider trades of Giovanni Caforio.

SYK

653 shares

SYK

May 9, 2024

Received

BMY

440 shares

BMY

Oct 10, 2023

Charity

SYK

705 shares

SYK

May 10, 2023

Received

BMY

$17.92M

BMY at $74.65/share

Feb 6, 2023

Sale

BMY

$1.74M

BMY at $69.71/share

Sep 20, 2022

Sale

BMY

$3.59M

BMY at $71.84/share

Sep 15, 2022

Sale

BMY

$2.22M

BMY at $74.04/share

Jun 13, 2022

Sale

BMY

420 shares

BMY

Mar 21, 2022

Charity

BMY

$1.79M

BMY at $71.52/share

Mar 21, 2022

Sale

BMY

$2.01M

BMY at $67.00/share

Feb 24, 2022

Sale

Compensation History

See how much did Giovanni Caforio make over time.

In 2023, Giovanni Caforio's total compensation reached approximately $19.7 million, with his base salary being the most significant component. Notably, he received no cash bonuses that year, a reflection of his commitment to a compensation structure aligned with company performance. The lack of new stock grants during this period is interesting, as it indicates a focus on his salary and other non-cash benefits, like financial counseling and travel perks. Caforio’s earlier compensation packages included performance incentives tied to specific goals, but his recent pay reflects a more stable approach as he hands over control to his successor. His compensation philosophy mirrors the company's emphasis on long-term growth, ensuring that executive pay is linked directly to performance metrics, enhancing shareholder confidence.

Year

2023

Total Compensation

$2.49M

Salary

$1.75M

Board Justification

The compensation philosophy emphasizes aligning pay with performance and shareholder interests, focusing on long-term value creation.

Bonus

$0.00

Board Justification

No cash bonus was awarded for 2023.

Other

$734.61K

Board Justification

Includes financial counseling, executive physicals, air travel, and contributions to savings plans.

Restricted Stock

$0.00(0 RSU, MSU, PSU)

Board Justification

No additional stock awards were granted in 2023; all stock awards were from previous years.

Performance Metrics

Compensation is based on company performance metrics including revenue, operating margin, and total shareholder return.

Other Bristol-Myers Squibb CEOs

Here are other CEOs of Bristol-Myers Squibb

Lamberto Andreotti

Ex-CEO of Bristol-Myers Squibb

May 2010 - May 2015

Christopher Boerner

CEO of Bristol-Myers Squibb

November 2023 - Present